Literature DB >> 33497702

Early Inflammation in Muscular Dystrophy Differs between Limb and Respiratory Muscles and Increases with Dystrophic Severity.

Zachary M Howard1, Jeovanna Lowe1, Anton J Blatnik2, Deztani Roberts1, Arthur H M Burghes2, Shyam S Bansal3, Jill A Rafael-Fortney4.   

Abstract

Duchenne muscular dystrophy (DMD) is a genetic, degenerative, striated muscle disease exacerbated by chronic inflammation. Mdx mice in the genotypic DMD model poorly represent immune-mediated pathology observed in patients. Improved understanding of innate immunity in dystrophic muscles is required to develop specific anti-inflammatory treatments. Here, inflammation in mdx mice and the more fibrotic utrn+/-;mdx Het model was comprehensively investigated. Unbiased analysis showed that mdx and Het mice contain increased levels of numerous chemokines and cytokines, with further increased in Het mice. Chemokine and chemokine receptor gene expression levels were dramatically increased in 4-week-old dystrophic quadriceps muscles, and to a lesser extent in diaphragm during the early injury phase, and had a small but consistent increase at 8 and 20 weeks. An optimized direct immune cell isolation method prevented loss of up to 90% of macrophages with density-dependent centrifugation previously used for mdx flow cytometry. Het quadriceps contain higher proportions of neutrophils and infiltrating monocytes than mdx, and higher percentages of F4/80Hi, but lower percentages of F4/80Lo cells and patrolling monocytes compared with Het diaphragms. These differences may restrict regenerative potential of dystrophic diaphragms, increasing pathologic severity. Fibrotic and inflammatory gene expression levels are higher in myeloid cells isolated from Het compared with mdx quadriceps, supporting Het mice may represent an improved model for testing therapeutic manipulation of inflammation in DMD.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33497702      PMCID: PMC8147105          DOI: 10.1016/j.ajpath.2021.01.008

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Chemokine receptor CCR2 involvement in skeletal muscle regeneration.

Authors:  Gordon L Warren; Tracy Hulderman; Dawn Mishra; Xin Gao; Lyndell Millecchia; Laura O'Farrell; William A Kuziel; Petia P Simeonova
Journal:  FASEB J       Date:  2004-12-15       Impact factor: 5.191

2.  CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis.

Authors:  Samira Tamoutounour; Sandrine Henri; Hugues Lelouard; Béatrice de Bovis; Colin de Haar; C Janneke van der Woude; Andrea M Woltman; Yasmin Reyal; Dominique Bonnet; Dorine Sichien; Calum C Bain; Allan McI Mowat; Caetano Reis e Sousa; Lionel F Poulin; Bernard Malissen; Martin Guilliams
Journal:  Eur J Immunol       Date:  2012-10-17       Impact factor: 5.532

Review 3.  Regulatory interactions between muscle and the immune system during muscle regeneration.

Authors:  James G Tidball; S Armando Villalta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-10       Impact factor: 3.619

4.  Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.

Authors:  Jill A Rafael-Fortney; Neeraj S Chimanji; Kevin E Schill; Christopher D Martin; Jason D Murray; Ranjit Ganguly; Jenna E Stangland; Tam Tran; Ying Xu; Benjamin D Canan; Tessily A Mays; Dawn A Delfín; Paul M L Janssen; Subha V Raman
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

5.  Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy.

Authors:  S Armando Villalta; Hal X Nguyen; Bo Deng; Tomomi Gotoh; James G Tidball
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

6.  Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice.

Authors:  Christophe Combadière; Stéphane Potteaux; Mathieu Rodero; Tabassome Simon; Adeline Pezard; Bruno Esposito; Régine Merval; Amanda Proudfoot; Alain Tedgui; Ziad Mallat
Journal:  Circulation       Date:  2008-03-17       Impact factor: 29.690

Review 7.  Reparative inflammation takes charge of tissue regeneration.

Authors:  Michael Karin; Hans Clevers
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

8.  Dystrophin deficiency promotes leukocyte recruitment in mdx mice.

Authors:  Simon Alexander Kranig; Raphaela Tschada; Maylis Braun; Christian Patry; Johannes Pöschl; David Frommhold; Hannes Hudalla
Journal:  Pediatr Res       Date:  2019-05-15       Impact factor: 3.756

9.  Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2.

Authors:  Kamalika Mojumdar; Feng Liang; Christian Giordano; Christian Lemaire; Gawiyou Danialou; Tatsuma Okazaki; Johanne Bourdon; Moutih Rafei; Jacques Galipeau; Maziar Divangahi; Basil J Petrof
Journal:  EMBO Mol Med       Date:  2014-11       Impact factor: 12.137

10.  CX3CR1 differentiates F4/80low monocytes into pro-inflammatory F4/80high macrophages in the liver.

Authors:  Young-Sun Lee; Myung-Ho Kim; Hyon-Seung Yi; So Yeon Kim; Hee-Hoon Kim; Ji Hoon Kim; Jong Eun Yeon; Kwan Soo Byun; Jin-Seok Byun; Won-Il Jeong
Journal:  Sci Rep       Date:  2018-10-10       Impact factor: 4.379

View more
  7 in total

1.  Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts.

Authors:  Maxime R F Gosselin; Virginie Mournetas; Malgorzata Borczyk; Suraj Verma; Annalisa Occhipinti; Justyna Róg; Lukasz Bozycki; Michal Korostynski; Samuel C Robson; Claudio Angione; Christian Pinset; Dariusz C Gorecki
Journal:  Elife       Date:  2022-09-27       Impact factor: 8.713

Review 2.  Mineralocorticoid Receptor Signaling in the Inflammatory Skeletal Muscle Microenvironments of Muscular Dystrophy and Acute Injury.

Authors:  Zachary M Howard; Chetan K Gomatam; Arden B Piepho; Jill A Rafael-Fortney
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 3.  Application of Droplet Digital PCR Technology in Muscular Dystrophies Research.

Authors:  Ioana Lambrescu; Alexandra Popa; Emilia Manole; Laura Cristina Ceafalan; Gisela Gaina
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

4.  Myeloid mineralocorticoid receptors contribute to skeletal muscle repair in muscular dystrophy and acute muscle injury.

Authors:  Zachary M Howard; Neha Rastogi; Jeovanna Lowe; J Spencer Hauck; Pratham Ingale; Chetan Gomatam; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Shyam S Bansal; Jill A Rafael-Fortney
Journal:  Am J Physiol Cell Physiol       Date:  2022-01-19       Impact factor: 4.249

5.  Non-Invasive Optical Motion Tracking Allows Monitoring of Respiratory Dynamics in Dystrophin-Deficient Mice.

Authors:  Angelika Svetlove; Jonas Albers; Swen Hülsmann; Marietta Andrea Markus; Jana Zschüntzsch; Frauke Alves; Christian Dullin
Journal:  Cells       Date:  2022-03-07       Impact factor: 6.600

Review 6.  Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy.

Authors:  Yasunari Matsuzaka; Yukihiko Hirai; Kazuo Hashido; Takashi Okada
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

7.  Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosis.

Authors:  Valentina Taglietti; Kaouthar Kefi; Iwona Bronisz-Budzyńska; Busra Mirciloglu; Mathilde Rodrigues; Nastasia Cardone; Fanny Coulpier; Baptiste Periou; Christel Gentil; Melissa Goddard; François-Jérôme Authier; France Pietri-Rouxel; Edoardo Malfatti; Peggy Lafuste; Laurent Tiret; Frederic Relaix
Journal:  Acta Neuropathol Commun       Date:  2022-04-25       Impact factor: 7.578

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.